PRIMA BIOMED
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima‘s lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission, and soon starting a pilot trial for resected pancreatic cancer. Prima BioMed is listed on the Australian stock exchange, on the NASDAQ in the US and in Germany on the Deutsche Börse in an entry standard.
PRIMA BIOMED
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2001-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.primabiomed.com.au
Total Employee:
11+
Status:
Closed
Contact:
+49 6139 8245254
Email Addresses:
[email protected]
Technology used in webpage:
All-Inkl
Similar Organizations
Fast BioPharma
Fast BioPharma Ltd. develops therapeutic products for treatment of cancer.
Tapestry Pharmaceuticals
Tapestry Pharmaceuticals is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer.
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-10-02 | Immutep | Immutep acquired by Prima Biomed | 28 M USD |
Official Site Inspections
http://www.primabiomed.com.au
- Host name: dd51818.kasserver.com
- IP address: 85.13.130.203
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Prima Biomed"
Prima BioMed Changes its Name to Immutep Ltd
Jay Campbell, Vice President of Business Development and Investor Relations, Prima BioMed +1 (917) 860-9404; [email protected]. Matthew Beck, The Trout Group LLC +1 …See details»
Immutep - Crunchbase Company Profile & Funding
Immutep is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Immutep is …See details»
Prima BioMed Becomes Immutep
Nov 29, 2017 Jay Campbell, Vice President of Business Development and Investor Relations, Prima BioMed +1 (917) 860-9404; [email protected]. Matthew Beck, The …See details»
Prima BioMed Changes Its Name to Immutep Ltd - GlobeNewswire
Nov 20, 2017 Jay Campbell, Vice President of Business Development and Investor Relations, Prima BioMed +1 (917) 860-9404; [email protected] Matthew Beck, The …See details»
Name change for Prima BioMed - Biotech
Oct 24, 2017 A change for Prima BioMed (ASX:PRR) with the company seeking shareholder support to adopt a new name, Immutep. In a letter to shareholders in advance of its annual general meeting in November, the company's chair, …See details»
Prima BioMed Ltd. - Company Profile & Staff Directory - ContactOut
Discover Prima BioMed Ltd. company details, including staff directory, contact information, and industry insights. Explore alternatives, competitors, and frequently asked questions to get …See details»
Organization | Prima BioMed - Purdue University
Prima BioMed Report issue For profit Phase 1 Phase 2 Phase 3 Founded: Sydney Australia (2001)See details»
Prima Biomed Ltd Company Summary & News ASX:PRR
Prima Biomed (ASX:PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is …See details»
Prima BioMed Ltd - VentureRadar
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic...See details»
Prima BioMed Ltd. - Armadale, Australia - bionity.com
Aug 11, 2011 Prima BioMed Ltd announced that its subsidiary company, Oncomab Pty Ltd has entered into a licensing agreement for the development of a Cripto-1 cancer ... Read news . 01 …See details»
PRIMA BIOMED LTD (ASX.PRR) | InvestoGain Australia
PRIMA BIOMED LTD (PRR) (This company subsequently changed its name to IMMUTEP LIMITED. You should refer to that name for Status.) Date of Listing: 23 June 1988: …See details»
PRIMA BIOMED TO PRESENT AT REGEN MED INVESTOR DAY …
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 9276 1284 www.primabiomed.com.au ABN: 90 009 237 889 ... advocacy …See details»
Prima Biomed - Financial Review
Nov 23, 2017 Prima BioMed topped capital raisings on Tuesday after it announced a recent share purchase plan had closed oversubscribed and raised $20.3 million. Other raisers on …See details»
Cancer sniper Prima BioMed rebrands to Immutep as it zeroes in …
Nov 22, 2017 Cancer drug developer Prima BioMed has cemented its focus on immunotherapy, changing its name to Immutep as it heads into further trials for treatment of advanced breast …See details»
ann - Prima BioMed appoints Chief Operating Officer - HotCopper
Prima BioMed Ltd , Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889 ... SPRI Clinical Trials, an …See details»
PRIMA BIOMED CHANGES ITS NAME TO IMMUTEP LTD
Jay Campbell, Vice President of Business Development and Investor Relations, Prima BioMed +1 (917) 860-9404; [email protected] . Matthew Beck, The Trout Group LLC …See details»
Prima BioMed Ltd - Cruelty Free Investing
Prima BioMed Ltd. is a biotechnology company, which engages in developing oncology therapies in the field of immunotherapy. Its lead product is IMP321, which involves in clinical …See details»
PRR News, Analysis, Announcements & Results | Prima Biomed | AFR
Nov 23, 2017 The latest Prima Biomed [PRR] news, articles, data and analysis from The Australian Financial ReviewSee details»
PRIMABioMed's obtains pivotal patent for dendritic cell.
Sep 1, 2002 PRIMABioMed Limited (Victoria, Australia)), a cancer and immunotherapy research and therapeutic development company, announced that a pivotal patent application for Cancer …See details»